Apps

openserveblockversewordysbillionaire.aiyourlistWhiteboardAppquizieunschool

News

Home
Politics
World
Sports
Markets
Business
Entertainment
Music
Health
Tech
Science
Good News

Want your own hosted, self-optimizing clone of this — or any OpenServe site? Open Development for enterprise →

© OpenServe Holdings LLC

Privacy Notice Data rights Terms of Service Feedback Cookie NoticeHelp Acceptable Use Copyright AI Notice Your Privacy Choices Subprocessors Data Processing Addendum Installed App Terms Company Solutions Free assessment Investors Get the app Contact

IJR News — today's news from every side

LEO Pharma plans $435M Dersimelagon rights deal — Aug 18, 2026LEO Pharma agreed to acquire worldwide rights to dersimelagon from Tanabe Pharma for up to $435 million, aiming to bring a late-stage oral MC1R agonist for EPP and XLP to market pending FDA approval. The deal reflects LEO’s strategy to grow its medical dermatology portfolio, backed by Phase 3 results, fast-track and orphan drug designations, and a planned 2027 launch if approved.